Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.8, 2005-01, pp. : 721-730

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By Ko Seung Sang Jordan V Craig

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 657-674

Informa Healthcare

Access to resources Recommend Favorite

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1081-1081

Informa Healthcare

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis

By Devogelaer J-P.

Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. : 141-154

Adis International

Access to resources Recommend Favorite

Raloxifene: A Review of its Use in Postmenopausal Osteoporosis

By Clemett D. Spencer C.M.

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 379-411

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

By Glimelius Bengt

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 417-433

Adis International

Access to resources Recommend Favorite